



**ASX Announcement**

**13<sup>th</sup> July 2023**

## **Atomo Completes Placement and Launches SPP**

### **Highlights**

- Atomo receives commitments for approximately \$1.25m via a Placement at A\$0.036 per share.
- The Company will also offer a Share Purchase Plan (**SPP**) of approximately A\$2.75m.
- The Company has also received a binding commitment for an up to A\$1.0m SPP shortfall placement if the SPP raises less than A\$1m, ensuring a minimum of \$2.25m in gross proceeds will be received across the Placement and SPP
- The Placement received strong support from domestic and offshore institutional investors.
- The SPP will provide all eligible shareholders the opportunity to participate in the transaction.
- Funds raised will be used to expand and accelerate sales, marketing, business development and new product registration activities with a focus on the US market following the recent FDA 510(k) approval for Lumos Diagnostics' FedbriDx test on the Atomo Pascal platform

**SYDNEY, Australia, 13 July 2023** Atomo Diagnostics Limited (ASX:AT1) (**Atomo** or the **Company**) is pleased to announce it has received binding commitments for a share placement (Placement) to institutional and sophisticated investors. The Placement will raise approximately A\$1.25 million in gross proceeds and is expected to settle on 18 July 2023.

The Placement will result in the issue of approximately 35.0 million shares at A\$0.036 per share (**Placement Shares**), within the Company's existing placement capacity under ASX Listing Rules 7.1. The issue price represents a 30.8% discount to the last closing price on 10 July 2023, being the last day the Company traded prior to the Placement.



The Company will also offer eligible shareholders in Australia, New Zealand and the United Kingdom the opportunity to participate in a Share Purchase Plan (**SPP**). Eligibility will be determined as at 7.00pm on the Record Date of 12 July 2023.

Eligible shareholders will be entitled to apply for up to A\$30,000 of new fully paid ordinary shares, targeting an additional A\$2.75m in gross proceeds. The Company reserves the right to accept oversubscriptions under the SPP, subject to the ASX Listing Rules and the Corporations Act 2001.

The terms and conditions of the SPP will be set out in an SPP Offer Booklet which is expected to be dispatched to eligible shareholders on 18 July 2023.

The SPP will be offered at the lower of:

- A\$0.036 per share; and
- a 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP, rounded to the nearest half cent.

The Company has applied to ASX for a waiver of Listing Rule 7.1, to permit the Company to offer new shares under the SPP, without shareholder approval, at the lower of A\$0.036 per share or a 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP, rounded to the nearest half cent (**Waiver**). In the event that the Waiver is not granted, the Company intends to seek shareholder approval to issue the new shares under the SPP (along with any shortfall under the SPP, if any), and the issue of new shares under the SPP would be conditional on receipt of such shareholder approval.

The Company's Directors reserve the right to participate in the SPP. Any issue of new shares under the SPP to Directors or their nominees will be subject to shareholder approval which will be sought at the Company's 2023 AGM.

The Company has received a binding commitment for a placement of up to A\$1m at the same price as the SPP in the event that less than A\$1m is raised under the SPP. This commitment will be reduced (pro rata) to the extent of the funds raised under the SPP. Any shares issued pursuant to such commitment will be issued without disclosure to an institutional investor and within the Company's placement capacity under Listing Rule 7.1.



Funds raised will be used to expand and accelerate sales, marketing, business development and new product registration activities with a focus on the US market following the recent FDA 510(k) approval for Lumos Diagnostics' FedbriDx test on the Atomo Pascal platform.

All shares issued under the Placement and SPP will rank equally with existing fully paid shares in Atomo.

Atomo CEO and Managing Director, John Kelly said: "We are pleased to announce the completion of our capital raise by way of placement, and the opening up of our SPP to enable all of our more than 7,500 shareholders the opportunity to participate. The recent FDA 510(k) approval received by Lumos Diagnostics for its FebriDx test, which is on the Atomo Pascal platform, provides a great opportunity for Atomo to accelerate its US market entry, both with potential OEM partners interested in utilising our award-winning products in the US market, and also for our 'ultra early' detection blood-based pregnancy test. With the additional funding, we are well positioned to capitalise on this milestone and progress US market entry, and to continue to bring our innovative products to key global markets. We thank investors and shareholders for their ongoing support and welcome further participation in the upcoming SPP."

Bell Potter Securities Limited is sole Lead Manager and bookrunner to the capital raising.

### Key Dates for Capital Raising

Event	Timing (Sydney time)
Record Date for the SPP	7.00pm Wednesday, 12 July 2023
Capital raising announced and trading halt lifted	Thursday, 13 July 2023
SPP Offer opens	Tuesday, 18 July 2023
Settlement of the Placement	Tuesday, 18 July 2023
Allotment of New Shares under the Placement	Wednesday, 19 July 2023
Commencement of trading of New Shares under Placement	Thursday, 20 July 2023
SPP closes	Tuesday, 1 August 2023
Announcement of results of SPP	By noon, Tuesday 8 August 2023



Allotment of New Shares under the SPP	Tuesday, 8 August 2023
Commencement of trading of New Shares under SPP	Wednesday, 9 August 2023

This timetable is indicative only and subject to change. The Company reserves the right to alter the above dates at any time, including amending the period for the SPP offer or accepting late applications, either generally or in particular cases, at its discretion and without notice to you, subject to the ASX Listing Rules, the Corporations Act 2001 (Cth) and any other applicable rules. The commencement of trading and quotation of new shares under the Placement and SPP offer is subject to ASX confirmation.

For more information, please contact:

John Kelly  
Managing Director & CEO  
Atomo Diagnostics  
[john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
Phone: +61 401 922 279

*This announcement was authorised by the Managing Director and CEO.*

**-Ends-**

#### **Webinar**

Atomo is pleased to invite shareholders and other investors to an Investor Webinar hosted by CEO and Managing Director, John Kelly and CFO, Will Souter to discuss the capital raising and provide an update on the Company's activities.

The webinar will be held on **Thursday 13 July 2023 at 12.00pm (midday) AEST.**

Topic: Atomo Diagnostics Limited (AT1.ASX) - Investor Webinar

Register in advance for this webinar:

[https://bellpotter.zoom.us/webinar/register/WN\\_VA8bst4OR3GsU3j0YcA-wA](https://bellpotter.zoom.us/webinar/register/WN_VA8bst4OR3GsU3j0YcA-wA)

#### **About Atomo**

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.



Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com)